Medtronic plc, a global leader in healthcare technology, today announced the launch of the Avalus Ultra™ Bioprosthesis valve in Western Europe during the EACTS annual congress in Lisbon. The Avalus Ultra valve, engineered for ease of use at implant and lifetime patient management, is Medtronic’s most advanced surgical aortic tissue valve built on 10 years of clinical experience with the Avalus™ valve..

医疗保健技术的全球领导者美敦力公司今天在里斯本举行的EACTS年度大会上宣布在西欧推出Avalus Ultra™生物瓣膜。Avalus Ultra瓣膜是美敦力公司最先进的外科主动脉组织瓣，其设计便于植入和终身患者管理，是基于10年Avalus™瓣膜的临床经验而构建的。。

The Avalus Ultra valve brings ease of use at implant, clear visibility for potential TAV-in-SAV procedures, and industry-leading Effective Orifice Areas (EOA) with long-term valve durability based on a decade of clinical experience with the Avalus valve.9,10,11 More specifically, the Avalus Ultra surgical valve has:.

Avalus Ultra瓣膜在植入时易于使用，在SAV手术中可以清晰地看到潜在的TAV，并且基于十年的Avalus瓣膜临床经验，具有长期瓣膜耐久性的行业领先的有效孔口面积（EOA）。9,10,11更具体地说，Avalus Ultra外科瓣膜具有：。

A low valve profile designed to facilitate ease of use at implant.1,2 with industry-leading EOA that may allow for greater blood flow that is supported by the clinical evidence of the Avalus valve5,6

一种低瓣膜外形，旨在促进植入物的易用性。1,2具有业界领先的EOA，可以允许更大的血流，这是由Avalus瓣膜的临床证据支持的5,6

A polyetheretherketone (PEEK) base frame, which provides a durable foundation to maintain valve circularity3, 4

聚醚醚酮（PEEK）基架，为保持阀门的圆形性提供了耐用的基础3、4

A radiopaque coil for clear fluoroscopic visibility for potential TAV-in-SAV procedures7,8

一种不透射线的线圈，用于SAV程序中潜在TAV的清晰荧光透视可见度7,8

“We are thrilled to further expand access to the Avalus Ultra valve by launching in Western Europe at the prominent EACTS annual congress,” said Karim Bandali, Ph.D., president of the Cardiac Surgery business within the Cardiovascular Portfolio at Medtronic. “The Avalus Ultra valve launch builds on several successful innovation launches this year, including the acquisition and launch of the Penditure™ Left Atrial Appendage (LAA) Exclusion System and the VitalFlow™ Extracorporeal Membrane Oxygenation (ECMO) system, making Medtronic Cardiac Surgery the most robust cardiac surgery portfolio offering available today.

美敦力心血管投资组合心脏外科业务总裁卡里姆·班达利博士说：“我们很高兴通过在西欧杰出的EACTS年度大会上推出Avalus Ultra瓣膜来进一步扩大使用范围。”。“Avalus Ultra valve的发布建立在今年几次成功创新发布的基础上，包括Penditure™左心耳（LAA）排除系统和VitalFlow™体外膜氧合（ECMO）系统的收购和发布，使美敦力心脏手术成为目前最强大的心脏手术产品组合。

This further demonstrates the company’s commitment to boldly invest in innovation across multiple cardiovascular and respiratory therapies to advance treatment options for more complex disease, and address clinicians’ growing need for managing patients holistically over their lifetime.”.

这进一步证明了该公司致力于大胆投资于多种心血管和呼吸疗法的创新，以推进更复杂疾病的治疗选择，并满足临床医生在一生中全面管理患者的日益增长的需求。”。

The first implantation of the Avalus Ultra valve in Western Europe occurred last week at the Heart Center in Leipzig, Germany, where Professor Michael Borger and his team successfully conducted two aortic valve replacements using the Avalus Ultra valve through minimally invasive access.

上周在德国莱比锡心脏中心首次植入了Avalus Ultra瓣膜，Michael Borger教授和他的团队通过微创途径成功地使用Avalus Ultra瓣膜进行了两次主动脉瓣置换术。

Additionally, at EACTS the 7-year outcomes from the PERIGON Pivotal Trial for the Avalus valve will be presented on Friday, Oct. 11th. The PERIGON Pivotal Trial is the largest prospective study of any contemporary stented surgical valve with more than 1,123 patients at 39 centers across eight countries.

此外，在EACTS上，10月11日（星期五）将介绍PERIGON Avalus瓣膜关键试验的7年结果。PERIGON Pivotal试验是当代支架手术瓣膜最大的前瞻性研究，在八个国家的39个中心有1123多名患者。

The Avalus Ultra valve is built on a decade of clinical experience with the Avalus valve.12.

Avalus Ultra瓣膜建立在Avalus瓣膜十年临床经验的基础上。

About Medtronic

关于美敦力

Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across more than 150 countries.

大胆思考。更大胆的行动。我们是美敦力。总部位于爱尔兰戈尔韦的美敦力公司是全球领先的医疗保健技术公司，通过寻找和寻找解决方案，大胆应对人类面临的最具挑战性的健康问题。我们的使命是减轻痛苦，恢复健康，延长寿命，我们团结了150多个国家的95000多名充满激情的全球团队。

Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day.

我们的技术和疗法治疗70种健康状况，包括心脏设备、手术机器人、胰岛素泵、手术工具、患者监测系统等。凭借我们丰富的知识、永不满足的好奇心以及帮助所有需要帮助的人的愿望，我们提供了创新技术，每秒钟、每小时、每天都在改变两个人的生活。

Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic, visit www.Medtronic.com and follow Medtronic on LinkedIn..

随着我们增强洞察力驱动的护理、以人为本的体验以及为我们的世界带来更好的结果，对我们的期望会更高。在我们所做的每件事中，我们都在创造非凡。有关美敦力的更多信息，请访问www.Medtronic.com并在LinkedIn上关注美敦力。。